Resor S R, Resor L D
Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY.
Neurology. 1990 Nov;40(11):1677-81. doi: 10.1212/wnl.40.11.1677.
We reviewed the charts of 84 patients with juvenile myoclonic epilepsy (JME) whom we had followed over the past 12 years, and identified 51 treated with acetazolamide (AZM) either because of a poor response to conventional antiepileptic drugs or to avoid valproate-associated adverse effects. Among the 51 we could isolate the effect of AZM on the generalized tonic-clonic seizures (GTCS) of JME in thirty-one. Chronic AZM monotherapy controlled GTCS in 14 of 31 patients. Most tolerated AZM very well; 5, however, developed renal calculi. Chronic AZM monotherapy controls GTCS in some patients with JME, but the development of renal calculi may limit its usefulness.
